Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:59
|
Bid Volume |
Ask
02/27/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
30.09
-0.81
(
-2.62% )
|
30.08
|
300 |
30.09
|
2,100 |
Analysis date: 24.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 30.01.2026.
Interest
Weak
Weak
Two stars since 24.02.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 20.02.2026 at a price of 29.53.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 24.02.2026.
4wk Rel Perf
-1.84%
-1.84%
The four-week dividend-adjusted underperformance versus SP500 is 1.84%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.53%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.85%.
Mkt Cap in $bn
4.84
4.84
With a market capitalization between $2 & $8bn, TG THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
0.97
0.97
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
11.23
11.23
The estimated PE is for the year 2028.
LT Growth
10.88%
10.88%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
50
50
For 1% of index variation, the stock varies on average by 0.50%.
Correlation
0.18
0.18
Stock movements are totally independent of index variations.
Value at Risk
13.71
13.71
The value at risk is estimated at USD 13.71. The risk is therefore 44.94%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
09.02.2021
09.02.2021